ARCHIVES

Nevins Retracts Key Paper By Duke Group, Raising Question Of Harm To Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 39 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

Centocor Withdraws Yondelis After FDA Calls for New Study

April 29, 2011

Grant Review: NIH Names Members To New Clinical Oncology Review Panel

February 26, 1999

In Brief: PHS Established Two Scientific Integrity Offices; Workshop On Ethical Issues Planned

August 18, 1989

FDA approves Irinotecan, Days After ODAC Meeting

June 21, 1996

GM To Offer Three Awards of $1000,000 Each To Cancer Investigators

September 8, 1978

In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month

August 14, 1992